期刊文献+

参麦注射液联合洛伐他汀治疗慢性心力衰竭疗效观察 被引量:4

The Effective Observation on Shenmai Injection with Lovastatin for Chronic Congestive Heart Failure
下载PDF
导出
摘要 目的观察参脉注射液联合洛伐他汀治疗慢性心力衰竭(CHF)的临床疗效及预后。方法将90例病人随机分为治疗组和对照组。两组均采用常规治疗,治疗组加用参麦注射液100mL加入5%葡萄糖250mL静脉输注,每日1次,2周后停用;联合应用洛伐他汀20mg,每晚1次,4周为1个疗程。结果治疗组总有效率、显效率分别为88.89%、60.00%,明显优于对照组的64.44%、42.22%(P<0.05)。结论参脉注射液联合洛伐他汀治疗CHF疗效肯定,并能明显改善病人的预后。 Objective To study the effect of Shennaai Injection and lovastatin on chronic congestive heart failure (CHF). Methods Ninety patients (pts) with CHF were divided into treatment group and control group at random. All pts were given regular treatment. Shennaai Injection was added in treatment group for 2 weeks and lovastatin 20 mg for 4 weeks. Results The total effective rate was 88.89% and the efficiency rate was 60.00% in treatment group. That were 64.44% and 42.22% in control group, respectively (P^0.05). Conclusion Shennaai Injection with lovastatin was more effective for CHF.
出处 《中西医结合心脑血管病杂志》 2008年第9期1018-1019,共2页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
关键词 参脉注射液 洛伐他汀 心力衰竭 慢性 Shennaai Injection Lovastatin chronic heart failure
  • 相关文献

参考文献9

二级参考文献41

  • 1Jianhui Zhu, Quyyumi AA, Norman JE, et al, Effects of total pathogen burden on coronary artery disease risk and C - reactive protein levels[J] .Am J Cardiol,2000,85 : 140 - 146.
  • 2Wolf MG,Zasmeta G, Homykewycz S, et al. Plasma levels of C - reactive prorein after coronary stent implantation[J] .Eur Heart J,2000,21:1152 - 1158.
  • 3Lenine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure[J]. N Eng J Med, 1990,323:236- 241.
  • 4Gabay C, Kushner I. Actue - phase proteins and other systemic responses to inflammation[J]. N Eng Med, 1999,340:448 - 454.
  • 5Tataru MC,Heinrich J,Junker R,et al.C - reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris[J]. Eur Heart J,2000,21 : 1000.
  • 6Albert MA, Staggers J, Chew P, et al. Investigators. The pravastatin inflammation CRP evaluation ( PRINCE ) : rationale and design [ J ]. Am Heart J,2001,141(6) :893 - 898.
  • 7Ridker PM, Rifai N, Clearfield M, et ,ak. Measurement - C - reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events[ J], N Engl J Med, 2001,344(26) : 1959 - 1965.
  • 8Bustos C, Hemandez- Presa MA, Ortego M, et al. HMG- COA reductase inhibition by atorvastatin reduces neointial inflammation in a rabbit model of atherosclerosis[J] .J AM Coll Cardiol, 1998,32(7) :2057 - 2064.
  • 9Torre - Amione - G, Kapadis - S, Benedia - S, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction :a report from the Study of Left Ventricular Dysfunction(SOLVD) J Am Coil Cardiol, 1996,27 (5): 1201.
  • 10Ho KKL, Anderson KM, Kannel WB. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation, 1993,88 ( 1 ): 107.

共引文献116

同被引文献4

  • 1中华人民共和国卫生部冲药新药临床研究指导原则[S].北京:中国医药科技出版社,2002.
  • 2中华人民共和国卫生部.中药新药临床研究指导原则[S].北京:中国医药科技出版社,1991.40.
  • 3陈灏珠,钟南山,陆再英.内科学[M].8版.北京:人民卫生出版社,2013:624-626.
  • 4无.慢性心力衰竭诊断治疗指南[J].中华心血管病杂志,2007,35(12):1076-1095. 被引量:3667

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部